Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1992 2
1993 1
1994 1
1995 3
1996 3
1997 2
1998 1
1999 5
2000 4
2001 1
2002 3
2003 2
2004 9
2005 6
2006 1
2007 6
2008 1
2009 3
2010 3
2011 5
2012 7
2013 4
2014 9
2015 8
2016 1
2017 1
2018 1
2019 3
2020 1
2021 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 22414633

98 results

Results by year

Filters applied: . Clear all
Page 1
Bone marrow dosimetry using 124I-PET.
Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA. Schwartz J, et al. J Nucl Med. 2012 Apr;53(4):615-21. doi: 10.2967/jnumed.111.096453. Epub 2012 Mar 13. J Nucl Med. 2012. PMID: 22414633 Free PMC article.
PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GA, Verheul HM, Menke CW, Huisman MC. Makris NE, et al. J Nucl Med. 2015 Feb;56(2):249-54. doi: 10.2967/jnumed.114.147819. Epub 2015 Jan 22. J Nucl Med. 2015. PMID: 25613538 Free article.
Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, Oyen WJ. Stillebroer AB, et al. J Nucl Med. 2012 Jan;53(1):82-9. doi: 10.2967/jnumed.111.094896. Epub 2011 Dec 12. J Nucl Med. 2012. PMID: 22159179 Free article. Clinical Trial.
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-López AJ. Wiseman GA, et al. Eur J Nucl Med. 2000 Jul;27(7):766-77. doi: 10.1007/s002590000276. Eur J Nucl Med. 2000. PMID: 10952488 Clinical Trial.
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.
O'Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, Larson SM. O'Donoghue JA, et al. J Nucl Med. 2011 Dec;52(12):1878-85. doi: 10.2967/jnumed.111.095596. Epub 2011 Nov 8. J Nucl Med. 2011. PMID: 22068895 Free PMC article. Clinical Trial.
Magnetic resonance imaging based bone marrow segmentation for quantitative calculation of pure red marrow metabolism using 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a novel application with significant implications for combined structure-function approach.
Basu S, Houseni M, Bural G, Chamroonat W, Udupa J, Mishra S, Alavi A. Basu S, et al. Mol Imaging Biol. 2007 Nov-Dec;9(6):361-5. doi: 10.1007/s11307-007-0112-5. Mol Imaging Biol. 2007. PMID: 17899296
98 results